O&G Vivas · Antenatal care — fetal medicine
Amniotic fluid disorders — structured oral station (12 minutes)
FRANZCOG oral-format station covering both polyhydramnios and oligohydramnios: thresholds, single deepest pocket versus AFI, the structured differentials, SMFM 46 management, the Potter sequence and the amnioinfusion evidence. Scored against the eight published RANZCOG oral domains.
On this page
Study tools
Target exams
Station format
4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex or unusual presentations; rapport; respect; communication. You are marked on how you behave as well as what you know.[1]
Reveal the examiner script and model responsesShowHide
Opening prompt — "Take the oligohydramnios case first. What is your threshold, and what is your first move?"
Model response — say it in this order: [2][5]
- "Oligohydramnios is a deepest vertical pocket under 2 cm or an amniotic fluid index under 5 cm. This woman meets both, so the diagnosis stands."
- "Before I act, I want to confirm the measurement — with colour Doppler turned off, because colour over-diagnoses oligohydramnios — and I want to exclude ruptured membranes. She describes a gush that settled, which makes preterm prelabour rupture the leading cause."
- "At the bedside I would take a focused history, perform a sterile speculum, send nitrazine, ferning and a PAMG-1 (AmniSure) test; ultrasound alone is a poor test of rupture with a sensitivity around 19%."[2]
Examiner is listening for: threshold, the method caveat (colour off, deepest pocket), and a structured differential by mechanism — under-production, loss, idiopathic. [2]
Probe 1 — "What is in your differential for oligohydramnios?"
- "By mechanism: under-production — renal agenesis or dysplasia, posterior urethral valves, placental insufficiency with growth restriction, postdates, maternal dehydration; loss — preterm or term prelabour rupture; and idiopathic."
- "The growth restriction here points me toward placental insufficiency, but the history of a gush makes rupture the priority to confirm. Oligohydramnios may also be the first sign of an undiagnosed renal anomaly in about 10% or an aneuploidy in about 13%, so I would complete the workup rather than reassure."[2][5]
Probe 2 — "Now the polyhydramnios case. Define it and walk me through your management."
- "Polyhydramnios is a deepest vertical pocket of 8 cm or more, or an amniotic fluid index of 24 cm or more (SMFM #46). This is moderate disease (AFI 30)."
- "My workup is a detailed anatomy scan looking for a swallowing failure — gastrointestinal obstruction, CNS lesion, hydrops — a repeat 75 g glucose tolerance test, TORCH and antibody screen."
- "Management follows SMFM #46: amnioreduction only for severe maternal discomfort or dyspnoea in severe polyhydramnios; indomethacin not for the sole purpose of reducing fluid; mild idiopathic needs no surveillance; severe polyhydramnios to a tertiary centre."[1]
Probe 3 — "She asks whether draining the fluid will fix it."
- "I would explain that amnioreduction is a temporiser, not a cure — the fluid re-accumulates, and repeat procedures carry PPROM, abruption and infection risk. The goal of the workup is to find and treat the cause; drainage is reserved for when the volume is causing her respiratory compromise."[1]
- "I would also flag the birth risks of an overdistended uterus — malpresentation, PPROM, cord prolapse, abruption, preterm birth, and postpartum haemorrhage — and plan an active third stage with uterotonics ready."[1][2]
Probe 4 — "Why do you use the deepest pocket rather than the amniotic fluid index?"
- "The Nabhan Cochrane pooled four trials and showed the amniotic fluid index over-diagnoses oligohydramnios (risk ratio 2.33), drives more inductions (RR 2.10) and more caesareans for fetal distress (RR 1.45), with no improvement in perinatal outcomes. For surveillance I use the single deepest pocket."[3]
Probe 5 — "The oligohydramnios woman turns out to have had PPROM at 19 weeks. She asks if restoring the fluid will help the baby's lungs."
- "I would counsel her honestly. The PPROMEXIL-III randomised trial gave weekly transabdominal amnioinfusion to women with second-trimester PPROM and a deepest pocket under 20 mm and found no reduction in perinatal mortality — 64% versus 75%, relative risk 0.86. Amnioinfusion is not standard treatment for mid-trimester PPROM."
- "The real risk is pulmonary hypoplasia and limb deformity — the Potter sequence — and I would involve the maternal-fetal medicine and perinatal palliative teams for honest prognosis and surveillance."[4][2]
Probe 6 — "How do you communicate the PPROM prognosis to her?"
This is a scored domain — demonstrate it out loud: [1]
- Sit at her level, use her name, and brief plainly: "Your waters broke early, which means the baby has very little fluid around them. That can affect how the lungs grow. We cannot replace the fluid in a way that has been shown to help, but we will watch closely and plan with you."
- Acknowledge uncertainty, allocate a staff member to support her and her partner, avoid jargon, and commit to a follow-up conversation and a written plan.[1]
References5ShowHide
- [1]Dashe JS, Pressman EK, Hibbard JU SMFM Consult Series #46: Evaluation and management of polyhydramnios Am J Obstet Gynecol, 2018.PMID 30048635
- [2]Dubil EA, Magann EF Amniotic fluid as a vital sign for fetal wellbeing Australas J Ultrasound Med, 2013.PMID 28191176
- [3]Nabhan AF, Abdelmoula YA Amniotic fluid index versus single deepest vertical pocket as a screening test for preventing adverse pregnancy outcome Cochrane Database Syst Rev, 2008.PMID 18646160
- [4]van Kempen LEM, van Teeffelen AS, de Ruigh AA, et al. Amnioinfusion compared with no intervention in women with second-trimester rupture of membranes: a randomized controlled trial Obstet Gynecol, 2019.PMID 30531572
- [5]Sherer DM A review of amniotic fluid dynamics and the enigma of isolated oligohydramnios Am J Perinatol, 2002.PMID 12152144